To learn if belzutifan can help to control the disease in patients with metastatic RCC who are considered candidates for active surveillance and have not under…

Active SurveillanceClear Cell Renal Cell Carcinoma

~Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07023432

Phase 2

Phase II Trial of In-Situ Autologous Vaccination With Intratumoral and Systemic Hiltonol® (Poly-ICLC) Administered to Prostate Cancer Patients on Active Surveillance

This is a partially blinded randomized controlled phase II pilot study comparing Poly-ICLC (Hiltonol®) treatment vs no treatment, for prostate cancer participa…

Prostate Cancer Patients on Active Surveillance

~Estimated

~$10 – $7,500

Ashutosh Kumar TewariNCT06343077